|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on August 22, 2002; DOI 10.1182/blood-2002-03-0756.
HEMATOPOIESIS
From the Laboratory of Chemical Biology, National
Institute of Diabetes and Digestive and Kidney Diseases, National
Institutes of Health, Bethesda, MD.
A cytokine-screening assay of cultured peripheral blood cells
obtained using immune rosetting and separation of progenitors was
developed to identify determinants of fetal hemoglobin (HbF) modulation
during adult erythropoiesis. Among the 12 erythroid growth-promoting
cytokines tested, stem cell factor (SCF) at a concentration of 50 ng/mL
resulted in the most significant increase in cell proliferation
and HbF content. The average HbF/hemoglobin A (HbA) ratio was
30.9% ± 18.7% in cultures containing SCF compared with
4.1% ± 2.2% in those grown with erythropoietin (EPO) alone (P = 8.5E-8). To further investigate the
hemoglobin-modulating effects of SCF, we examined the surface
expression pattern of the SCF receptor, CD117, among maturing
erythroblasts. CD117 expression increased during the first week of
culture and peaked on culture days 7 to 9. After culture day 9, the
level of CD117 declined to lower levels. The rise in CD117 expression
to high levels mirrored that of the transferrin receptor (CD71), and
the subsequent reduction in CD117 was inversely related to increases in
expression of glycophorin A. SCF-related increases in the HbF/HbA ratio
correlated with the expression pattern of CD117. SCF added during days
7 to 14 resulted in a more pancellular distribution of HbF on day 14 compared with the heterocellular distribution present in cultures
supplemented with SCF on days 0 to 7. A significant SCF-mediated
increase in HbF was also measured using progenitors derived from cord
blood. These results suggest that the HbF response to SCF is greatest at the late progenitor stage as a function of surface CD117 expression.
(Blood. 2003;101:492-497) A complete understanding of fetal hemoglobin (HbF)
production among adult erythroblasts is critical for the treatment of
sickle cell anemia and "Switching" of the dominant hemoglobin in circulating erythrocytes
from the fetal to adult type is usually completed during infancy.
However, some individuals continue to have increased expression of HbF
later in their lives.7 In many cases, those individuals
possess elevations in HbF content due to large deletions involving the
In this report, we compare a dozen hematopoietic growth-promoting
cytokines for their HbF-modulating effects by screening matched
cultures of primary human erythroblasts. SCF produced the most
significant and consistent increase in the HbF content in the
cells of several donors. Although an SCF response was consistently demonstrated, the absolute increase in HbF- hemoglobin A (HbA) varied
considerably among donors. SCF was further examined to determine
whether effects on HbF were varied according to erythroid development
and maturation. SCF effects on HbF appeared to be greater at later
stages of erythroblast maturation and correlated well with a highly
regulated pattern of CD117 (c-kit; SCF receptor) expression. A
significant SCF effect on HbF was also detected using progenitor cells
derived from cord blood.
Culture and analysis of primary cells from human blood
Immunostaining and flow cytometry
HPLC of hemoglobin Cells were lysed in deionized sterile water, by repeated freezing and thawing. Cell debris was removed by filtration through Ultrafree-MC devices (Millipore, Bedford, MA) before cation-exchange chromatography. Hemoglobin species from cell lysates were separated on a 20 × 4-mm POLYCATA column (Poly LC, Columbia, MD) fitted to a Gilson HPLC system (Gilson, Middleton, WI). The hemoglobin was eluted during 4 minutes 8% to 40% gradient of buffer B (20 mM Bis-Tris [tris(hydroxymethyl)aminomethane], 2 mM KCN, 200 mM NaCl, pH 6.55 ) in buffer A (20 mM Bis-Tris, 2 mM KCN, pH 6.96 ) according to the manufacturer's protocol. Hemoglobin proteins were detected by absorbance measurements at 415 nm. Ratios of HbF/HbA were calculated by integration of the areas under the HbF and HbA peaks using software supplied by the manufacturer and expressed as percentage values. Two-tailed, paired t tests were used for all statistical analyses. Confirmation of HbF and HbA retention times in experimental samples was performed by electrospray mass spectroscopy (Hewlett-Packard Series 1100). Purified HbF and HbA (Perkin-Elmer Wallac) were used for reference.
Screening assay of growth-associated cytokines For the purpose of screening cytokines and other biologically active molecules for possible effects on hemoglobin modulation during erythropoiesis, we used a single-phase culture system of progenitor cells from the buffy coats of healthy blood donors. This single-phase culture system used negative selection as the method for obtaining progenitor cells, and the cells were obtained from the buffy coats of blood donations rather than mobilized apheresis products as we have previously described.20 Once isolated, the cell populations were cultured at an initial concentration of approximately 104 cells/mL for 14 days in EPO-containing (4 U/mL) medium. After 14 days, the cells were counted and the ratio of fetal and adult hemoglobin (HbF/HbA) was determined on the basis of HPLC analyses. In cultures supplemented with EPO alone and no additional cytokines, an average of 8 million erythroid precursor cells per unit of donated blood (3.8 ± 0.2 E05 cells/mL culture medium) were generated after the 14-day culture period. Overall, the HbF/HbA ratio averaged 3.9% ± 0.2% after the 14-day culture period in EPO without additional cytokines.Based on the desired effects of EPO on erythroblast proliferation and
hemoglobin content, cells from 35 additional individuals were used in
an initial cytokine screening assay. From each individual, the cells
were initially divided into matched sets to ensure proper control of
patient-specific results. In one flask, the cells were cultured in EPO
alone as a control. The paired flask from each donor was grown in the
presence of EPO plus an additional cytokine. After 14 days, results
from duplicate or triplicate cultures were examined to quantitate
differences in cell growth or HbF (Table 1). For this study, a dozen cytokines
were screened on the basis of previous reports suggesting a possible
association with erythroid growth using other culture systems. In
cases where previous reports were unavailable, the cytokines were added
at low and high concentrations for measurement of a possible dose
effect (higher concentrations shown in Table 1). No significant
erythroid growth was detected in control cells grown in the cytokines
alone in the absence of EPO (not shown). In the presence of EPO,
cytokine-specific effects on proliferation and hemoglobin content were
detected. The majority of cytokines tested had no significant effects
on cell growth or HbF/HbA in this culture system.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and
interleukin 3 (IL-3) caused no significant increase in HbF/HbA, but did
stimulate cell division. Supplementing IL-6 or SCF to the
EPO-containing medium resulted in a significant change
(P
Due to the dramatic effect of SCF on growth and HbF/HbA, this cytokine
was studied further. First, we tested several additional donors to
determine the reproducibility and variability of SCF effects on HbF/HbA
(Figure 1). Buffy coats from a total of
19 blood donors were studied as matched culture pairs. Consistent with
the screening studies, the HbF/HbA ratios for cells grown in EPO plus
SCF were significantly higher than in EPO alone (EPO alone,
4.1% ± 2.2%; EPO + SCF, 30.9% ± 18.7%;
P = 8.5E-08). Whereas an SCF-related increase in
HbF/HbA was measured in cultures from every donor, the range of
response was broad with HbF/HbA ratios from 17% to 91% (Figure 1B).
To determine if the donors with a large response had inherently high
HbF values in vivo, HPLC analyses were performed on their
peripheral blood erythrocytes. No donor-specific correlation was
identified, and the erythrocytes had a lower distribution of HbF than
the cells cultured in either EPO or EPO plus SCF (erythrocyte HbF/HbA,
0.8% ± 0.8%; P = 1.9E-06).
SCF receptor (CD117) expression is regulated during erythropoiesis SCF exerts its effects on eukaryotic cells through dimerization of the membrane protein CD117.21 Therefore, to determine the level of surface CD117 expression on differentiating erythroblasts, cells grown in EPO alone were sampled every 3 days and stained with labeled anti-CD117 monoclonal antibody (Figure 2). As shown, the percentage of cells expressing CD117 at significant levels increased during the first week in culture. On day 6, 98% had detectable CD117 expression. Thereafter, the percentage of cells with detectable levels gradually declined with less than 25% positive by day 12. In addition to the total percentage of cells expressing CD117, it is important to also note changes in the level of CD117 expression among those positive cells. By day 6, a distinct population of larger cells was clearly detected with CD117 expressed at relatively high levels (third decade of fluorescence). Although cells expressing high-level CD117 persisted on day 9, they were no longer detected by day 12. When EPO and SCF were added on day 0, the CD117 signal remained low for the first 48 hours followed by a delayed increase during the first week and lower peak levels compared to cells cultured in EPO alone. In triplicate analyses, the mean CD117 fluorescence on culture day 6 in EPO alone was 13.3 fluorescence units compared with 3.8 fluorescent units in matched cultures containing EPO plus SCF.
To place the rise and subsequent fall of CD117 into the context of other markers of erythroid development, the cells were also stained for transferrin receptor (CD71) and GPA expression. These surface proteins have been demonstrated to provide flow cytometric correlates of the developmental stage of the erythroblasts.20 CD71 expression at very high levels is the hallmark of the onset of hemoglobin production at the preproerythroblast-proerythroblast stage of differentiation. GPA is expressed later relative to CD71 and marks the transition toward terminal maturation. Among the cells studied here, the transition from mid- to high-level CD117 mirrored that of CD71 on days 3 to 6. However, unlike CD71, a decline in the expression of CD117 coincided with the onset of GPA expression at higher levels. Dual staining demonstrated that GPA expression at high levels directly coincided with the loss of CD117 (data not shown). Hence, CD117 expression appears to be highly regulated in adult erythroid cells with an initial rise to very high levels in proerythroblasts followed by a rapid decline associated with terminal differentiation. SCF modulation of HbF correlates with CD117 expression Based on the highly regulated pattern of SCF expression on the erythroblast membrane, the temporal pattern of SCF effects on HbF according to the developmental stage of the cells was studied. For this purpose, SCF was added at delayed time intervals in the culture period and HPLC was performed to determine the HbF/HbA ratio (Figure 3). Cells from each donor were divided into 6 matched aliquots in separate flasks and cultured for 2 weeks. SCF was then added to individual flasks after 3-day intervals as shown. On day 14, the cells from all the flasks were harvested and the HbF/HbA ratios were calculated from HPLC profiles. Cell counts at that time revealed a progressive decline from 3.0 × 106 cells/mL in the presence of SCF on days 0 to 14 to 2.0 × 105 cells/mL in the absence of SCF. In contrast to the gradual reduction in cell counts, a significant reduction in the SCF effect on HbF was not noted until day 12 when the HbF/HbA ratio returned to levels similar to that in the control flask supplemented with EPO alone. Notably, high-level expression of CD117 expression was no longer present by day 12. The maximum effect on the HbF/HbA ratio occurred when SCF was added at the end of 1 week, that is, when CD117 was expressed at its highest level at the proerythroblast stage of development. This pattern was reproduced in cultured cells from 3 separate donors (HbF/HbA ratio, EPO alone on days 0-14, 3.7% ± 1.3%; EPO days 0-14 plus SCF on days 0-14, 23% ± 12%; SCF days 3-14, 33% ± 21%; SCF days 6-14, 48.3% ± 18.6%; SCF days 9-14, 38% ± 9.8%; SCF days 12-14, 6.2% ± 1.4%).
Early versus late effects of SCF on HbF modulation Based on the unexpectedly high level of HbF/HbA on delayed addition of SCF, we next compared the SCF added during the first week (early) versus the second week (late) in culture. This approach was used to differentiate SCF effects in cells with rising levels of CD117 and the onset of hemoglobin production (week 1) versus those populations with falling levels of CD117 and established hemoglobin production (week 2). On day 14, the HbF/HbA ratios were calculated in matched cultures under these conditions and the distribution of HbF was measured by flow cytometry. As shown, the distribution of HbF+ cells on culture day 14 was heterocellular in the presence of EPO alone (Figure 4, left panel). Similarly, a heterocellular pattern of HbF-based fluorescence was detected when SCF was present on days 0 to 7 (48% compared with 33% in EPO alone). This increase in HbF+ cells correlated with a small increase in relative HbF content (HbF/HbA, 5.0% ± 1.7% compared to EPO alone, 2.2% ± 1.1%). When SCF addition was delayed until the second week, a pancellular distribution of HbF+ cells (93% over background fluorescence) was detected and the HbF/HbA ratio increased significantly (20% ± 6.1%). The flow cytometric analysis also demonstrated that the population with higher HbF levels included the larger cells. Cytospin preparations confirmed that those larger cells had a proerythroblast morphology consistent with the reported ability of SCF to partially inhibit erythroid maturation.22
SCF effect in cord blood-derived progenitors Progenitor cells derived from cord blood were also studied using this culture model in the presence or absence of SCF. Cord blood-derived erythroblasts demonstrate the same pattern of an initial rise followed by a reduction of CD117 expression as adult peripheral blood-derived cells (data not shown). In the absence of SCF, erythroid differentiation of cultured cord blood progenitor cells expressed both HbF and HbA in a pancellular fashion (Figure 5). When SCF (50 ng/mL) was added on days 7 to 14 to cord blood cultures, a pancellular distribution of HbF and HbA was still present. However, the HPLC profiles showed that SCF caused a pronounced rise in the HbF content of the cells to dominant levels with the mean HbF/HbA ratio increasing from 136% ± 25% in EPO alone to 295% ± 34% in EPO plus SCF (P = .004). This novel result demonstrates that SCF has a significant effect on the HbF content of cultured erythroid progenitor cells circulating at the time of birth. In addition, this result demonstrates SCF-mediated increases in HbF among populations already expressing this hemoglobin with a pancellular distribution.
In this report, we have begun to explore the hypothesis that modulation of HbF may result from signal transduction involving fully committed erythroblasts. This hypothesis arose from the demonstration that HbF and HbA share a coordinated rather than "switched" expression pattern during adult human erythropoiesis.20 Our matched-culture strategy using primary cells from peripheral blood was developed to screen several growth-related cytokines for possible effects on hemoglobin modulation. In the absence of additional cytokines, the progenitor cells from those healthy blood donors proliferated and differentiated into populations containing 95% or more GPA+ erythroblasts with a HbF/HbA of less than 5% after 14 days in EPO-supplemented culture medium. Of note, these results using mononuclear cells from a relatively large number of blood donations demonstrated a nearly identical in vitro pattern of erythroid development to that of mobilized CD34+ cells.20 Several of the tested cytokines did not significantly affect hemoglobin modulation with the screening assay described here, but formal dose titration and cytokine combinations must be performed before their effects on erythropoiesis are fully understood. As an initial screen, this primary cell culture system appears to be well suited for testing other cytokines, pharmacologic agents, or mixtures thereof. Among the cytokines demonstrating significant effects on hemoglobin modulation, SCF was studied further based on its dramatic effects on HbF and cell proliferation as shown here and elsewhere.17-19 SCF caused a consistent rise in HbF/HbA among 19 healthy blood donors, but the magnitude of the SCF response was highly variable. Host response variability has similarly been identified in the response of HbF-modulating agents used in patients with hemoglobinopathies.23,24 The flow cytometric analyses of the SCF receptor (CD117) expression demonstrated a highly regulated pattern during human erythropoiesis. Of particular interest was the demonstration of increased CD117 expression to higher levels coincidental with the rise in CD71 expression. Initial increases in CD117 expression were followed several days later by a decline to lower levels associated with the expression of GPA at high levels on the erythroblast surface. Hence, the highest level of CD117 expression was present in cells having a CD71hi, GPAlow cellular phenotype. This phenotype has been previously shown to identify committed, rapidly proliferating erythroblasts.20 The increased expression of CD71 also correlates with the onset of hemoglobin production at low levels in each cell.20 Consistent with the increased level of CD117, cells at this developmental stage also appear to be the most sensitive to SCF (compare Figures 4 and 5). Furthermore, the decline of CD117 from the cell surface toward the end of the culture period corresponded to a loss of SCF effect. We conclude that CD117 expression is highly regulated during erythroid differentiation and that the magnitude of SCF-mediated effects is proportionate to the extent of CD117 expression on the cell surface. Although not studied here, others have shown that HbF-modulating effects of SCF on erythroblasts are maintained in circulating erythrocytes in vivo.25 While designing these studies, we predicted that increases in the HbF/HbA ratio would be greatest after continuous exposure to SCF on days 0 to 14. However, cells cultured in the same concentration of SCF only during the second week resulted in higher HbF/HbA ratios at the end of the 14-day period. This unexpected result may be related to the initial loss of SCF-bound CD117 from the cell surface. After SCF dimerizes CD117 on the cell surface, the receptor-ligand complexes are internalized and degraded.21 Unlike the recycling of transferrin receptor to the cell surface after transferrin internalization, CD117 is not recycled and receptor levels on the cell surface are down-regulated until new CD117 is produced. We speculate that the internalization SCF-CD117 complexes from the surface of immature cells provide an autoregulatory mechanism for SCF effects in more mature human erythroblasts. This type of ligand-dependent regulation of receptor expression in erythroblasts could provide the basis for differences in the HbF production associated with acute and chronic states of stress or other transitions in hemoglobin production.14 Whether the high serum SCF levels associated with stress erythropoiesis in humans27 correlates with lower CD117 levels in bone marrow erythroblasts is unknown. HbF modulation during erythroid stress in vivo will likely involve additional factors including signaling from both soluble and transmembranous forms of SCF, local concentrations of additional cytokines, and interactions between erythroblasts and other cells in the marrow. We were unable to identify any special population of erythroid progenitors that were recruited by the addition of SCF during the earliest period of erythroid development. The HbF distribution in the presence of SCF during the first week was nearly identical to that of cells cultured in EPO alone (Figure 4). This result challenges the assumption that hemoglobin-modulating effects of SCF are greatest at the earliest stages of erythropoiesis. In this study, the most significant effect of SCF on HbF modulation occurred in late progenitors as CD117 increased just prior to the terminal stages of differentiation. This "late" effect of SCF in human cells was not predicted from nonhuman models because EPO down-regulates the expression of c-kit among murine progenitor cells within 3 hours.26 SCF altered the erythroid program of the adult cells as reflected by the significant increase in the HbF/HbA ratio and the increased distribution in HbF. In cord blood-derived populations, the HbF/HbA ratio rose to HbF-dominant levels. In addition, the response in cord blood-derived progenitor cells suggests that SCF modulates hemoglobin by increasing its expression in cells already producing the protein in addition to the "reactivation" of HbF in adult cells. The developmental program of committed human erythroblasts is neither fixed nor determined exclusively by EPO. Germline mutations in either murine SCF (Steel factor) or CD117 (c-kit) result in severe anemia in the mouse.28 Multiple intracellular signaling pathways are involved in the SCF response primarily through the control of gene transcription.29,30 In erythroid cells, integration of EPO and SCF signaling may occur at the level of their membrane receptors31 or within downstream pathways.32 The first evidence that SCF possessed hemoglobin-modulating properties in addition to its effect on erythroid growth was derived from in vitro assays using the cells of patients with sickle cell disease.17 Although questioned by some,27,33 these results have been reproduced here and by others.18,25 Recently, an elegant unicellular system has been reported to demonstrate clonal SCF-mediated HbF modulation at very early stages of erythropoiesis.19 Our data suggest that SCF effects on HbF are not restricted to the earliest erythroblasts, but may be even more dramatic among more mature erythroblast populations as a function of increased CD117 expression on their membranes. We propose that consecutive generations of human erythroblasts possess hemoglobin programs that are dynamic and determined, at least in part, by the environment in which those cells arise.
We thank the blood donors and the National Institutes of Health Department of Transfusion Medicine for kindly providing the cells used in this study. Dr Alan Schechter is recognized for helpful discussions and critical reading of the manuscript.
Submitted March 11, 2002; accepted August 12, 2002.
Prepublished online as Blood First Edition Paper, August 22, 2002; DOI 10.1182/blood-2002-03-0756.
U.W. and K.R.L. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Jeffery L. Miller, Laboratory of Chemical Biology, Bldg 10, Rm 9B17, National Institutes of Health, Bethesda, MD 20892; e-mail: jm7f{at}nih.gov.
1. Watson J, Stahman AW, Bilello EP. The significance of the paucity of sickle cells in newborn negro infants. Am J Med Sci. 1948;215:419-423[Medline] [Order article via Infotrieve]. 2. Perrine RP, Brown MJ, Clegg JB, et al. Benign sickle-cell anaemia. Lancet. 1972;2:1163-1167[CrossRef][Medline] [Order article via Infotrieve]. 3. Pembrey ME, Wood WG, Weatherall DJ, et al. Fetal haemoglobin production and the sickle gene in the oases of eastern Saudi Arabia. Br J Haematol. 1978;40:415-429[Medline] [Order article via Infotrieve]. 4. Atweh GF, Schechter AN. Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol. 2001;8:123-130[CrossRef][Medline] [Order article via Infotrieve]. 5. Atweh GF, Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin Hematol. 2001;38:367-373[CrossRef][Medline] [Order article via Infotrieve].
6.
Mentzer WC, Kan YW.
Prospects for research in hematologic disorders: sickle cell disease and thalassemia.
JAMA.
2001;285:640-642 7. Wood WG. Increased HbF in adult life. Baillieres Clin Haematol. 1993;6:177-213[CrossRef][Medline] [Order article via Infotrieve].
8.
Gilman JG, Huisman TH.
DNA sequence variation associated with elevated fetal G gamma globin production.
Blood.
1985;66:783-787
9.
Garner CP, Tatu T, Best S, et al.
Evidence of genetic interaction between the 10. Craig JE, Rochette J, Fisher CA, et al. Dissecting the loci controlling fetal haemoglobin production on chromosomes 11p and 6q by the regressive approach. Nat Genet. 1996;12:58-64[CrossRef][Medline] [Order article via Infotrieve].
11.
Dover GJ, Smith KD, Chang YC, et al.
Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2.
Blood.
1992;80:816-824 12. Sheridan BL, Weatherall DJ, Clegg JB, et al. The patterns of fetal haemoglobin production in leukaemia. Br J Haematol. 1976;32:487-506[Medline] [Order article via Infotrieve]. 13. Alter BP. Fetal erythropoiesis in stress hematopoiesis. Exp Hematol. 1979;7:200-209. 14. Stamatoyannopoulos G, Veith R, Galanello R, et al. Hb F production in stressed erythropoiesis: observations and kinetic models. Ann N Y Acad Sci. 1985;445:188-197[Abstract]. 15. Gabbianelli M, Pelosi E, Valtieri M, et al. A model for reactivation of hemoglobin F synthesis in normal adult erythropoiesis. Ann N Y Acad Sci. 1990;612:196-206[CrossRef][Medline] [Order article via Infotrieve].
16.
Migliaccio AR, Migliaccio G, Brice M, et al.
Influence of recombinant hematopoietins and of fetal bovine serum on the globin synthetic pattern of human BFUe.
Blood.
1990;76:1150-1157
17.
Miller BA, Perrine SP, Bernstein A, et al.
Influence of Steel factor on hemoglobin synthesis in sickle cell disease.
Blood.
1992;79:1861-1868
18.
Peschle C, Gabbianelli M, Testa U, et al.
c-kit ligand reactivates fetal hemoglobin synthesis in serum-free culture of stringently purified normal adult burst-forming unit-erythroid.
Blood.
1993;81:328-336
19.
Gabbianelli M, Testa U, Massa A, et al.
Hemoglobin switching in unicellular erythroid culture of sibling erythroid burst-forming units: kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate.
Blood.
2000;95:3555-3561
20.
Wojda U, Noel P, Miller JL.
Fetal and adult hemoglobin production during adult erythropoiesis: coordinate expression correlates with cell proliferation.
Blood.
2002;99:3005-3013
21.
Broudy VC, Lin NL, Buhring HJ, et al.
Analysis of c-kit receptor dimerization by fluorescence resonance energy transfer.
Blood.
1998;91:898-906
22.
Muta K, Krantz SB, Bondurant MC, et al.
Stem cell factor retards differentiation of normal human erythroid progenitor cells while stimulating proliferation.
Blood.
1995;86:572-580
23.
Rodgers GP, Dover GJ, Uyesaka N, et al.
Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
N Engl J Med.
1993;328:73-80
24.
Atweh GF, Sutton M, Nassif I, et al.
Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease.
Blood.
1999;93:1790-1797 25. Lavelle D, Molokie R, Ducksworth J, et al. Effects of hydroxurea, stem cell factor, and erythropoietin in combination on fetal hemoglobin in the baboon. Exp Hematol. 2001;29:156-162[CrossRef][Medline] [Order article via Infotrieve]. 26. Ohneda O, Yanai N, Obinata M. Combined action of c-kit and erythropoietin on erythroid progenitor cells. Development. 1992;114:245-252[Abstract]. 27. Croizat H, Nagel RL. Circulating cytokines response and the level of erythropoiesis in sickle cell anemia. Am J Hematol. 1999;60:105-115[CrossRef][Medline] [Order article via Infotrieve]. 28. Russell ES. Hereditary anemias of the mouse: a review for geneticists. Adv Genet. 1979;20:357-459[Medline] [Order article via Infotrieve]. 29. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol. 1999;31:1053-1074[CrossRef][Medline] [Order article via Infotrieve]. 30. Taylor ML, Metcalfe DD. Kit signal transduction. Hematol Oncol Clin North Am. 2000;14:517-535[CrossRef][Medline] [Order article via Infotrieve]. 31. Wu H, Klingmuller U, Besmer P, et al. Interaction of the erythropoietin and stem-cell-factor receptors. Nature. 1995;21;377:242-246.
32.
Pircher TJ, Geiger JN, Zhang D, et al.
Integrative signaling by minimal erythropoietin receptor forms and c-Kit.
J Biol Chem.
2001;276:8995-9002
33.
Papayannopoulou T, Brice M, Blau CA.
Kit ligand in synergy with interleukin-3 amplifies the erythropoietin-independent, globin-synthesizing progeny of normal human burst-forming units-erythroid in suspension cultures: physiologic implications.
Blood.
1993;81:299-310
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. Gabbianelli, O. Morsilli, A. Massa, L. Pasquini, P. Cianciulli, U. Testa, and C. Peschle Effective erythropoiesis and HbF reactivation induced by kit ligand in -thalassemia Blood, January 1, 2008; 111(1): 421 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Aerbajinai, J. Zhu, Z. Gao, K. Chin, and G. P. Rodgers Thalidomide induces {gamma}-globin gene expression through increased reactive oxygen species mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis Blood, October 15, 2007; 110(8): 2864 - 2871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Amoyal, E. Prus, and E. Fibach Vanadate Elevates Fetal Hemoglobin in Human Erythroid Precursors by Inhibiting Cell Maturation Experimental Biology and Medicine, May 1, 2007; 232(5): 654 - 661. [Abstract] [Full Text] [PDF]
|
|
Top
Abstract
Introduction
thalassemia. HbF prevents polymerization of hemoglobin S (HbS) in all newborns until HbS becomes the dominant hemoglobin in circulating erythrocytes.
-globin gene
transcription during adult life. Other families have elevations in HbF
that are linked to separate genomic regions.
5 M
.05) in HbF/HbA and cell proliferation.
